Loading…
Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.
Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.
Is paid by contract: some clients buy scientists' time by the hour or project, others lease dedicated labs and teams for several years, which makes revenue steadier. Large pharma partners such as Bristol Myers Squibb and Amgen have dedicated research centres there. Biocon, founded by Kiran Mazumdar-Shaw, is the majority shareholder.
In one line: India's smaller WuXi AppTec/Lonza peer for pharma CRO/CDMO services.
Moat: narrow (process know-how, customer qualification, regulatory licence). Biocon Group backing plus dedicated, long-term R&D partnerships with major global pharma clients.
Headquarters: Bengaluru, India · Founded: 1993 · Employees: 8,376
Size Syngene International (SYNGENE.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $1.78B, the 399th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹417.30 on 6 Nov 2026.
Performance Over six months the shares fell 10.7%, against -2.0% for the median peer and 0.0% for the India market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +11.7%); the operating margin is 13.0% (peer median 11.9%).
Valuation It trades at 67.8× forward earnings against a peer median of 21.4× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.1 points below its cost of capital (15.2% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹35.2B | ₹37.4B | ₹36.4B | ₹34.9B | ₹31.9B |
| Revenue growth | — | +3% | +4% | +9% | — |
| Gross profit | ₹11.4B | ₹9.84B | ₹10.2B | ₹10.3B | ₹9.36B |
| EBITDA | ₹9.07B | ₹9.97B | ₹10.5B | ₹10.8B | ₹9.94B |
| Net income | ₹1.86B | ₹3.17B | ₹4.96B | ₹5.10B | ₹4.64B |
| Free cash flow | n/a | ₹6.11B | ₹4.44B | ₹6.03B | ₹3.36B |
| Capital expenditure | n/a | ₹3.68B | ₹7.70B | ₹5.11B | ₹5.18B |
| Total debt | ₹5.07B | ₹4.58B | ₹5.78B | ₹5.55B | ₹8.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Syngene International SYNGENE.NS | $1.78B | -11% | -6% | 13% | 67.8× | 35.3% |
| SAI Life Sciences SAILIFE.NS | $4.02B | +64% | +27% | 21% | 89.2× | n/a |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYNGENE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.8% | +3.5% | 4th highest of 21 |
| 6-month return | -10.7% | -2.0% | 10th lowest of 21 |
| Distance from 52-week high | -38.5% | -30.7% | 8th lowest of 21 |
| Revenue growth (TTM) | -6.0% | +11.7% | 3rd lowest of 19 |
| Operating margin | 13.0% | 11.9% | 10th highest of 20 |
| Forward P/E | 67.8× | 21.4× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 35.3% | 3.6% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +11.4% | +10.2% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | +23.9 pp | -9.0 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -8.1 pp | +1.1 pp | 3rd lowest of 18 |
| EV / EBITDA | 18.5× | 11.7× | 3rd most expensive of 8 |
| Net debt / EBITDA | -0.0× | 1.6× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Syngene International SYNGENE.NS | India | $1.78B | -11% | -6% | 13% | 67.8× | 35.3% | +11.4% |
| Prosegur Compania de Seguridad PSG.MC | Spain | $1.79B | +9% | +1% | 6% | 11.8× | -5.3% | +6.7% |
| China Conch Venture 0586.HK | Hong Kong | $1.79B | -36% | +21% | 18% | 5.5× | n/a | n/a |
| Hoist Finance HOFI.ST | Sweden | $1.79B | +29% | +16% | 30% | 11.9× | n/a | n/a |
| Choice International CHOICEIN.NS | India | $1.76B | +8% | +34% | 27% | 49.8× | n/a | n/a |
| Beijing Orient EcoEnergy 002310.SZ | China | $1.81B | -24% | +35% | 12% | n/a | 36.4% | -47.6% |
| Ipsos IPS.PA | France | $1.74B | -3% | +3% | 12% | 7.0× | -10.8% | +6.6% |
| GRG Metrology & Test 002967.SZ | China | $1.72B | -16% | +13% | 13% | 22.7× | 3.9% | +14.4% |
| Visual China 000681.SZ | China | $1.71B | -25% | -9% | 4% | 44.0× | n/a | n/a |
| Teemsun Technology 301571.SZ | China | $1.86B | 0% | +61% | 22% | n/a | n/a | n/a |
| Focus Technology 002315.SZ | China | $1.86B | -1% | +14% | 24% | 22.1× | 3.2% | +10.6% |
| International Gemological Institute IGIL.NS | India | $1.86B | +12% | +21% | 58% | 24.4× | 14.6% | +37.6% |
| Guangdong Feinan Resources Recycling 301500.SZ | China | $1.68B | -31% | +42% | 7% | n/a | n/a | n/a |
| Insperity NSP | United States | $1.90B | +53% | +2% | 0% | 19.9× | 19.5% | +9.7% |
| Jiangsu Guotai International 002091.SZ | China | $1.91B | -11% | +7% | 6% | 10.0× | -20.9% | +5.5% |
| Kruk KRU.WA | Poland | $1.65B | -22% | +8% | 77% | 6.9× | -2.1% | +16.8% |
| Xi'an Taijin New Energy & Materials Sci-Tech 688813.SS | China | $1.93B | -13% | n/a | n/a | n/a | n/a | n/a |
| Healthcare Services HCSG | United States | $1.64B | +5% | +4% | 6% | 20.6× | 3.4% | +0.9% |
| Heron Neutron Medical 7799.TW | Taiwan | $1.94B | +15% | n/a | -5,071% | 380.6× | n/a | n/a |
| Anhui XDLK Microsystem 688582.SS | China | $1.95B | -36% | -38% | 21% | 37.3× | 55.7% | +37.0% |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.61B | +16% | +11% | 11% | 44.6× | 27.8% | +14.1% |